MIEF1 and glioblastoma: Genome-wide and transcriptome-wide analyses confirmed minimal off-target effects, highlighting the potential of d3A/CRISPR-directed methylation as a safe and effective therapeutic strategy to enhance TMZ chemosensitivity in GBM [52].